Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
120,781,538
-
Total 13F shares
-
68,742,401
-
Share change
-
+3,047,118
-
Total reported value
-
$937,662,508
-
Put/Call ratio
-
39%
-
Price per share
-
$13.64
-
Number of holders
-
114
-
Value change
-
+$43,941,561
-
Number of buys
-
63
-
Number of sells
-
45
Institutional Holders of Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) as of Q1 2019
As of 31 Mar 2019,
Coherus Oncology, Inc. - Common Stock, par value $0.0001 per share (CHRS) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,742,401 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Temasek Holdings (Private) Ltd, JPMORGAN CHASE & CO, BlackRock Inc., FMR LLC, Kohlberg Kravis Roberts & Co. L.P., VANGUARD GROUP INC, Sofinnova Investments, Inc., Rubric Capital Management LP, and CITADEL ADVISORS LLC.
This page lists
114
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.